Results 131 to 140 of about 7,222 (160)
Neutralization and Anti-S Antibody Titers in SARS-CoV-2 Boosted Adults in Mexico: A Comparison Across Five Vaccine Types. [PDF]
Int J MicrobiolBlas N +10 more
europepmc +1 more source
Vaccines, 2023 (1) Background: This study aimed to compare the immunogenicity of the mix-and-match CoronaVac/BNT162b2 vaccination to the homologous CoronaVac/CoronaVac regimen. (2) Methods: We conducted a simple-blinded randomized superiority trial to measure SARS-CoV-2 neutralization antibodies and anti-spike receptor binding domain (RBD) IgG concentrations in blood
Samar Samoud +2 more
exaly +5 more sources
Vaccines, 2023 Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has outpaced vaccine availability and delivery from vaccine manufacturers, and thus, a scarcity of vaccines happened to many countries around the world. In Thailand, the mixing of different types of vaccines was approved and clinically implemented partially due to ...
Suriyon Uitrakul +2 more
exaly +5 more sources
An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey [PDF]
Journal of Medical Virology, 2022 AbstractLimited data are available on the short‐ to midterm levels of antibodies to the CoronaVac vaccine and quantitative change in humoral response after homologous or heterologous booster doses. In this prospective cohort study, we evaluated the anti‐receptor‐binding domain (RBD) immunoglobulin G (IgG) levels after two doses of CoronaVac and ...
Derya Çaǧlayan +2 more
exaly +5 more sources
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial [PDF]
Nature Medicine, 2022 AbstractThe emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant
Jingxin Li, Lihua Hou, Xiling Guo
exaly +6 more sources
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID ‐19 vaccines in Hong Kong
Respirology, 2022 BACKGROUND AND OBJECTIVE: Few head-to-head evaluations of immune responses to different vaccines have been reported. METHODS: Surrogate virus neutralization test (sVNT) antibody levels of adults receiving either two doses of BNT162b2 (n = 366) or ...
Chris Ka Pun Mok +2 more
exaly +2 more sources
Lancet, The, 2021 Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2.
Mine Durusu Tanriover +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Dynamics of antibody response to CoronaVac vaccine
Journal of Medical Virology, 2022AbstractCoronaVac was the first vaccine approved in Brazil for use in healthcare workers (HCWs). However, there is limited information about it, with little long‐term evidence on post‐vaccination antibody persistence. This study evaluated the antibody response to SARS‐CoV‐2 in 1237 HCWs after the first (1D), second dose (2D), and 6 months ...
Marcela Helena Gambim Fonseca +2 more
exaly +3 more sources